News

The trial is the second phase 1 safety clinical study of XF-73, which evaluated its potential to cause dermal irritation when applied topically. Destiny Pharma has designed the

Imbruvica in combination with obinutuzumab is said to be the first approved non-chemotherapy combination regimen for treatment-naïve patients with CLL/SLL, which is the most common form of leukemia

The financing is designed to support Orion’s investments into research and development, thus backing the creation of new medicines, in the fields of oncology and neurological and respiratory

The acquisition is expected to be completed in the summer of 2019. The companies are entering into a strategic partnership that will see NextPharma take over production of

The deal also provides Sobi with the right to participate in payments from the US profits or losses for new medicine MEDI8897 in development for RSV-induced LRTI As

The acquired rights will cover all potential indications in the hospital setting for the administration of inhaled AirNOvent at up to 80 parts per million. One of the

NV-5138 is a first-in-class, orally-active small molecule that directly activates mTORC1, the gatekeeper of cellular metabolism and renewal, which is suppressed in the brain of people suffering from

X-165 is a highly potent and selective small molecule inhibitor of Autotaxin owned by X-Rx. An initial advanced lead series that led to the identification of X-165 was

The second indication of Rubraca has been approved as monotherapy for the maintenance treatment of adults with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer